Serious diseases affecting the transparent part of the eye, called the cornea, are very difficult to treat because this ...
Zacks Investment Research on MSN
Glaukos launches Epioxa, boosts growth in corneal treatments
Glaukos Corporation GKOS recently announced the commercial availability of Epioxa, marking a significant milestone in its corneal health portfolio. The therapy stands out as the first FDA-approved, ...
Add Yahoo as a preferred source to see more of our stories on Google. The US Food and Drug Administration (FDA) has approved Glaukos Corporation’s Epioxa, offering patients living with a rare corneal ...
Please provide your email address to receive an email when new articles are posted on . Vyznova received regulatory approval in Japan for the treatment of bullous keratopathy. Injectable endothelial ...
Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, ...
Commercial rollout includes direct purchasing and specialty distribution, alongside scaled investments in awareness, education, screening, and diagnosis to drive earlier keratoconus detection. Epioxa ...
Prevent Blindness, the nation's leading patient advocacy organization dedicated to preventing blindness and preserving sight, has declared March 23-29, 2026, as its first-ever Keratoconus Week. The ...
Her five-year, $1.8 million R01 grant titled “Corneal Endothelium – Extracellular Matrix Interactions” is from the National Eye Institute. The cornea is a clear dome on the front of the eye that helps ...
Frequent dry eyes may signal more than simple irritation and could be an early warning sign of an autoimmune disease. This symptom has long been associated with Sjögren's Disease, a chronic autoimmune ...
Please provide your email address to receive an email when new articles are posted on . In an analysis of data from two phase 3, multicenter studies of 1,217 adult patients randomized to the ...
The A.A.O. recommends that adults with no signs or risk factors for eye disease get a comprehensive exam at 40 to establish a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results